Cited by 104Schizophrenia research and treatmentTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Khodaie-Ardakani, Mohammad-Reza, Mirshafiee, Omid, Farokhnia, Mehdi, Tajdini, Masih, Hosseini, Seyed-Mohammad-Reza, Modabbernia, Amirhossein, Rezaei, Farzin, Salehi, Bahman, Yekehtaz, Habibeh, Ashrafi, Mandana, Tabrizi, Mina, Akhondzadeh, Shahin·2014·Psychiatry Research

DOI 10.1016/j.psychres.2013.12.051

Open this paper in CoChat — free account

Abstract

The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabilized on risperidone for a minimum duration of eight weeks were recruited. The patients were randomly assigned to minocycline (titrated up to 200 mg/day) or placebo in addition to risperidone (maximum dose of 6 mg/day) for eight weeks. Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, and Extrapyramidal Syndrome Rating Scale were used. Thirty-eight patients completed the study. Significant time × treatment interaction for negative [F(2.254,85.638)=59.046, P<0.001] general psychopathology [F(1.703,64.700)=6.819, P=0.001], and positive subscales [F(1.655,62.878)=5.193, P=0.012] as well as total PANSS scores [F(1.677,63.720)=28.420, P<0.001] were observed. The strongest predictors for change in negative symptoms were the treatment group (β=-0.94, t=-10.59, P<0.001) followed by the change in PANSS positive subscale (β=-0.185, t=-2.075, P=0.045). Side effect profiles of the two treatment regimens were not significantly different. Minocycline seems to be an efficacious and tolerable short-term add-on to risperidone for treatment of negative and general psychopathology symptoms of schizophrenia.

Integrity signals

Registry

Crossref · 10.1016/j.psychres.2013.12.051

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P., Patel, R. N., Patel, I. R., & Abramson, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14014 · Cited by 474
Persistent Negative Symptoms in Schizophrenia: An Overview
Buchanan, R. W. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl057 · Cited by 443
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 424
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414

Show all 33 references

Sorted by citations

Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration
Dinan, T. G., & Cryan, J. F. (2017) · The Journal of Physiology · doi:10.1113/jp273106 · Cited by 813
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 376
Cross talk: the microbiota and neurodevelopmental disorders
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271
The impact of gut microbiota on brain and behaviour
Dinan, T. G., & Cryan, J. F. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000221 · Cited by 267
Microbes, immunity, and behavior: psychoneuroimmunology meets the microbiome
Dinan, T. G., & Cryan, J. F. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.103 · Cited by 246
An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis
Çakici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M., & Sommer, I. E. (2019) · Psychological Medicine · doi:10.1017/s0033291719001995 · Cited by 218
The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170
Treating Negative Symptoms in Schizophrenia: an Update
Remington, G. J., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., & Hahn, M. (2016) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-016-0075-8 · Cited by 167
Glutamatergic dysfunction in Schizophrenia
Kruse, A. O., & Bustillo, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02253-w · Cited by 162
Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis
Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132
Schizophrenia and the gut–brain axis
Nemani, K., Hosseini Ghomi, R., McCormick, B., & Fan, X. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.08.018 · Cited by 151
Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia
Giovanoli, S., Engler, H., Engler, A., Richetto, J., Feldon, J., Riva, M. A., Schedlowski, M., & Meyer, U. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.38 · Cited by 127
Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials
Cho, M., Lee, T. Y., Kwak, Y. B., Yoon, Y. B., Kim, M., & Kwon, J. S. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419835028 · Cited by 128
Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms
Cattane, N., Richetto, J., & Cattaneo, A. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.001 · Cited by 129
The role of the gut microbiome in the development of schizophrenia
Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G. A., & Dinan, T. G. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.010 · Cited by 121
A glial perspective on the extracellular matrix and perineuronal net remodeling in the central nervous system
Tewari, B. P., Chaunsali, L., Prim, C. E., & Sontheimer, H. W. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1022754 · Cited by 115
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D. T., Vyas, G. R., Richardson, C. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000345 · Cited by 103
Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double‐blind, placebo‐controlled trial
Arabzadeh, S., Ameli, N., Zeinoddini, A., Rezaei, F., Farokhnia, M., Mohammadinejad, P., Ghaleiha, A., & Akhondzadeh, S. (2015) · Bipolar Disorders · doi:10.1111/bdi.12324 · Cited by 101
Self-citation
Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial
Sepehrmanesh, Z., Heidary, M., Akasheh, N., Akbari, H., & Heidary, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.001 · Cited by 97
Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects
Nasyrova, R. F., Ivashchenko, D. V., Ivanov, M. V., & Незнанов, Н. Г. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00139 · Cited by 98
Minocycline in neurodegenerative and psychiatric diseases: An update
Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2020) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 94
Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials
Xiang, Y.-Q., Zheng, W., Wang, S.-B., Yang, X.-H., Cai, D.-B., Ng, C. H., Ungvari, G. S., Kelly, D. L., Xu, W.-Y., & Xiang, Y.-T. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.012 · Cited by 83
Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017) · CNS Spectrums · doi:10.1017/s1092852916000638 · Cited by 78
Modulating Neuroinflammation to Treat Neuropsychiatric Disorders
Radtke, F., Chapman, G., Hall, J., & Syed, Y. A. (2017) · BioMed Research International · doi:10.1155/2017/5071786 · Cited by 80
Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients
Emadi-Kouchak, H., Mohammadinejad, P., Asadollahi‐Amin, A., Rasoulinejad, M., Zeinoddini, A., Yalda, A., & Akhondzadeh, S. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000098 · Cited by 76
Self-citation
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Clinical management of negative symptoms of schizophrenia: An update
Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 76
Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta‐analysis of randomized controlled trials
Oya, K., Kishi, T., & Iwata, N. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2426 · Cited by 69
Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis
Panizzutti, B., Skvarc, D., Lin, S. C., Croce, S., Meehan, A., Bortolasci, C. C., Marx, W., Walker, A. J., Hasebe, K., Kavanagh, B. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065250 · Cited by 72
Minocycline combination therapy with fluvoxamine in moderate‐to‐severe obsessive–compulsive disorder: A placebo‐controlled, double‐blind, randomized trial
Esalatmanesh, S., Abrishami, Z., Zeinoddini, A., Rahiminejad, F., Sadeghi, M., Najarzadegan, M., Shalbafan, M., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12430 · Cited by 65
Self-citation
The microbiome and disorders of the central nervous system
Felice, V. D., & O'Mahony, S. M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.06.016 · Cited by 60
Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels
Zhang, L., Zheng, H., Wu, R., Zhu, F., Kosten, T. R., Zhang, X., & Zhao, J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.04.004 · Cited by 59
Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia
Wu, Q., Wang, X., Wang, Y., Long, Y., Zhao, J., & Wu, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00740-6 · Cited by 59
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double‐blind and placebo‐controlled trial
Iranpour, N., Zandifar, A., Farokhnia, M., Goguol, A., Yekehtaz, H., Ardakani, M. R. K., Salehi, B., Esalatmanesh, S., Zeionoddini, A., Mohammadinejad, P., et al. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2517 · Cited by 58
Self-citation
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial
Ghaleiha, A., Alikhani, R., Kazemi, M.-R., Mohammadi, M.-R., Mohammadinejad, P., Zeinoddini, A., Hamedi, M., Shahriari, M., Keshavarzi, Z., & Akhondzadeh, S. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0175 · Cited by 60
Self-citation
Anti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53
A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo
Murrough, J. W., Huryk, K. M., Mao, X., Iacoviello, B. M., Collins, K. A., Nierenberg, A. A., Kang, G., Shungu, D. C., & Iosifescu, D. V. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.067 · Cited by 54
The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies
Minichino, A., Brondino, N., Solmi, M., Del Giovane, C., Fusar-Poli, P., Burnet, P., Cipriani, A., & Lennox, B. R. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.012 · Cited by 50
Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial
Kianimehr, G., Fatehi, F., Hashempoor, S., Ardakani, M. R. K., Rezaei, F., Nazari, A., Kashani, L., & Akhondzadeh, S. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-55 · Cited by 50
Self-citation
A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression
Soczynska, J. K., Kennedy, S. H., Alsuwaidan, M. T., Mansur, R. B., Li, M., McAndrews, M. P., Brietzke, E. M., Woldeyohannes, H. O., Taylor, V. H., & McIntyre, R. S. (2017) · Bipolar Disorders · doi:10.1111/bdi.12496 · Cited by 49
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
Weiser, M., Levi, L. W., Burshtein, S., Chiriță, R., Cirjaliu, D., Gonen, I., Yolken, R. H., Davidson, M., Zamora, D., & Davis, J. M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.10.023 · Cited by 48
The role of the gut microbiota in schizophrenia: Current and future perspectives
Rodrígues-Amorím, D., Baltanás, T. R., Regueiro, B. J., Spuch, C., Heras, M. E. D. L., Méndez, R. V.-N., Nieto-Araujo, M., Barreiro-Villar, C., Olivares, J. M., & Agís‐Balboa, R. C. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1433878 · Cited by 51
Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia
Volk, D. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.019 · Cited by 47
Memantine in neurological disorders – schizophrenia and depression
Czarnecka, K., Chuchmacz, J., Wójtowicz, P., & Szymański, P. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01982-z · Cited by 48
Efficacy of Memantine in Schizophrenic Patients: A Systematic Review
Iorio, G. D., Baroni, G., Lorusso, M., Montemitro, C., Spano, M. C., & Giannantonio, M. D. (2017) · Journal of Amino Acids · doi:10.1155/2017/7021071 · Cited by 41
Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study
Amidfar, M., Khiabany, M., Kohi, A., Salardini, E., Arbabi, M., Azizi, M. R., Zarrindast, M., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12469 · Cited by 41
Self-citation
Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System
Dinesh, A. A., Islam, J., Khan, J., Turkheimer, F., & Vernon, A. C. (2020) · CNS Drugs · doi:10.1007/s40263-020-00765-x · Cited by 40
Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis
Hadi, F., Kashefinejad, S., Kamalzadeh, L., Hoobehfekr, S., & Shalbafan, M. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00534-6 · Cited by 36
Adjunctive minocycline for major mental disorders: A systematic review
Zheng, W., Zhu, X., Zhang, Q., Cheng, G., Cai, D.-B., He, J., Ng, C. H., Ungvari, G. S., Peng, X.-J., Ning, Y., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858286 · Cited by 38
Simvastatin adjunct therapy for negative symptoms of schizophrenia
Tajik-Esmaeeli, S., Zadeh, E. M., Abbasi, N., Shariat, S. V., Rezaei, F., Salehi, B., & Akhondzadeh, S. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000159 · Cited by 36
Self-citation
An emerging role of cGMP in the treatment of schizophrenia: A review
Shim, S. S., Shuman, M. D., & Duncan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.015 · Cited by 35
Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
Ansari, Z., Pawar, S. R., & Seetharaman, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2006514 · Cited by 35
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 33
A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia
Pérez‐Gómez, A., Carretero, M., Weber, N., Peterka, V., To, A., Titova, V., Solis, G. M., Osborn, O., & Petrascheck, M. (2018) · Nature Communications · doi:10.1038/s41467-018-07684-y · Cited by 35
Anti-inflammatory effects of minocycline are mediated by retinoid signaling
Clemens, V., Regen, F., Bret, N. L., Heuser, I., & Hellmann‐Regen, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0460-x · Cited by 34
Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study
Ardakani, M. R. K., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., Shams‐Alizadeh, N., Mohammad-karimi, M., Esfandiari, G.-R., Hajiaghaee, R., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.011 · Cited by 29
Self-citation
l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial
Zeinoddini, A., Ahadi, M., Farokhnia, M., Rezaei, F., Tabrizi, M. H., & Akhondzadeh, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.016 · Cited by 27
Self-citation
Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial
Jafari, S., Ashrafizadeh, S.-G., Zeinoddini, A., Rasoulinejad, M., Entezari, P., Seddighi, S., & Akhondzadeh, S. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12287 · Cited by 27
Self-citation
Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial
Mazinani, R., Nejati, S., & Khodaei, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.09.028 · Cited by 26
Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive–compulsive disorder: A double‐blind randomized trial with placebo control
Naderi, S., Faghih, H., Aqamolaei, A., Mortazavi, S. H., Mortezaei, A., Sahebolzamani, E., Rezaei, F., & Akhondzadeh, S. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12803 · Cited by 27
Self-citation
Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial
Hosseini, S. M. R., Farokhnia, M., Rezaei, F., Gougol, A., Yekehtaz, H., Iranpour, N., Salehi, B., Tabrizi, M. H., Tajdini, M., Ghaleiha, A., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.02.001 · Cited by 23
Self-citation
The Microbiota/Microbiome and the Gut–Brain Axis: How Much Do They Matter in Psychiatry?
Marazziti, D., Buccianelli, B., Palermo, S., Parra, E., Arone, A., Beatino, M. F., Massa, L., Carpita, B., Barberi, F. M., Mucci, F., et al. (2021) · Life · doi:10.3390/life11080760 · Cited by 23
A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders
Romero‐Miguel, D., Casquero‐Veiga, M., MacDowell, K. S., Torres-Sánchez, S., Garcia-Partida, J. A., Lamanna‐Rama, N., Romero‐Miranda, A., Berrocoso, E., Leza, J. C., Desco, M., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab036 · Cited by 21
Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia
Buonaguro, E. F., Tomasetti, C., Chiodini, P., Marmo, F., Latte, G., Rossi, R., Avvisati, L., Iasevoli, F., & de Bartolomeis, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658987 · Cited by 21
Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial.
Shakiba, M., Zadeh, E. M., Noorbala, A. A., Jafarinia, M., Divsalar, P., Kashani, L., Shahmansouri, N., Tafakhori, A., Bayat, H., & Akhondzadeh, S. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ajp.2018.28835.2020 · Cited by 21
Self-citation
Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia
Liu, F., Zhang, B., Xie, L., Ruan, Y., Xu, X., Zeng, Y., Messina, L. M., Zhao, J., & Fan, X. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.003 · Cited by 20
Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review
Rezaei, A., Moqadami, A., & Khalaj‐Kondori, M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02839-1 · Cited by 18
Is there a role of gut microbiota in mental health?
Lange, K. W., Lange, K. M., Nakamura, Y. K., & Kanaya, S. (2020) · Journal of Food Bioactives · doi:10.31665/jfb.2020.9213 · Cited by 17
Pharmacological Treatments of Negative Symptoms in Schizophrenia—An Update
Tsapakis, E.-M., Treiber, M., Mitkani, C. A., Drakaki, Z., Cholevas, A., Spanaki, C., & Fountoulakis, K. Ν. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185637 · Cited by 16
Investigation of TSPO Variants in Schizophrenia and Antipsychotic Treatment Outcomes
Pouget, J. G., Gonçalves, V. F., Nurmi, E. L., Laughlin, C., Mallya, K. S., McCracken, J. T., Aman, M. G., McDougle, C. J., Scahill, L. D., Misener, V. L., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.158 · Cited by 16
Connecting Neurobiological Features with Interregional Dysconnectivity in Social-Cognitive Impairments of Schizophrenia
Adraoui, F. W., Douw, L., Martens, G. J. M., & Maas, D. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097680 · Cited by 14
Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis
Etchecopar‐Etchart, D., Yon, D. K., Wojciechowski, P., Aballéa, S., Toumi, M., Boyer, L., & Fond, G. B. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102473 · Cited by 13
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 international guidelines for the management of patients with obsessive-compulsive disorder
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 12
An Integrated Multi-Omics Approach for AMR Phenotype Prediction of Gut Microbiota
Gao, P., Chen, Z., Wang, D., Huang, M., Ono, N., Altaf‐Ul‐Amin, M., & Kanaya, S. (2021) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm52615.2021.9669397 · Cited by 9
Minocycline as adjunct therapy for a male patient with deficit schizophrenia
Chen, X., Xiong, Z., Li, Z., Yang, Y., Zheng, Z., Li, Y., Xie, Y., & Li, Z. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s179658 · Cited by 9
Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
Deakin, J. F. W., John Suckling, A., Dazzan, P., Joyce, E. M., Lawrie, S. M., Upthegrove, R., Husain, N., Chaudhry, I. B., Dunn, G., Jones, P. B., et al. (2019) · Efficacy and Mechanism Evaluation · doi:10.3310/eme06070 · Cited by 8
Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials
Moccia, L., Bardi, F., Anesini, M. B., Barbonetti, S., Kotzalidis, G. D., Rossi, S., Caso, R., Grisoni, F., Mandracchia, G., Margoni, S., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030540 · Cited by 7
Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study
Herrero-Zazo, M., Brauer, R., Gaughran, F., Howard, L. M., Taylor, D. M., & Barlow, D. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117743483 · Cited by 6
Lessons From Clinical Trials of Immunomodulatory Drugs in Psychiatric Disorders
Pak, T. K., Haque, N., & Jha, M. K. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.11.009 · Cited by 5
Redox and Microglia in the Pathophysiology of Schizophrenia
Kato, T. A., Hyodo, F., Yamato, M., Utsumi, H., & Kanba, S. (2015) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.14-00235-4 · Cited by 5
No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia
Liu, F., Xie, L., Zhang, B., Ruan, Y., Zeng, Y., Xu, X., Zhao, J., & Fan, X. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000841 · Cited by 5
Neuroinflammation in Schizophrenia Focused on the Pharmacological and Therapeutic Evidence
Xu, H. (2015) · Pharmacologia · doi:10.5567/pharmacologia.2015.438.453 · Cited by 4
Gut-Brain Axis: The Role of Gut Microbiota in the Psychiatric Disorders
Evrensel, A., & Ceylan, M. E. (2015) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20150128123852 · Cited by 4
Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review
Zamani, Z., & Akhondzadeh, S. (2019) · Journal of Medicinal Plants · doi:10.29252/jmp.3.71.1 · Cited by 4
Self-citation
The Etiological Role of Impaired Neurogenesis in Schizophrenia: Interactions with Inflammatory, Microbiome and Hormonal Signaling
So, M. T.-W., Ullah, A., Waris, A., & Alhumaydhi, F. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199814 · Cited by 4
Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Arabzadeh, S., Zeinoddini, A., Mostafavi, S., Hamedi, M., Ehyaii, A., Ghaleiha, A., Zeinoddini, A., & Akhondzadeh, S. (2018) · Europe PMC (PubMed Central) · Cited by 3
Self-citation
Brief psychotic disorder related to areca nut use: a case report
Li, S., Li, Z., Chen, J., Wang, F., Ou, Y., Huang, Y., & Li, Z. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1360493 · Cited by 2
Early rebalancing of neuroinflammatory cascades lastingly rescues prefrontal deficits in a 22q11.2ds model
Günther, A., Chini, M., Bitzenhofer, S. H., Marquardt, A., & Hanganu‐Opatz, I. L. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106470 · Cited by 2
The Influence of Diet and the Gut Microbiota in Schizophrenia
Ghomi, R. H., & Nemani, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00016-5 · Cited by 2
The efficacy of complementary use of memantine in treatment of schizophrenia with chronic course
fakhkhari, A. (2013) · Cited by 2
Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders
Sogos, C., & Fioriello, F. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_20 · Cited by 2
Add-On Pharmacotherapy in Schizophrenia: Does It Improve Long-Term Outcomes? A Systematic Review
Smyrnis, A., Smyrnis, G., & Smyrnis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217847 · Cited by 2
Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis
Li, H., Shen, H., Duan, X., Guo, M., & Liu, X. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07774-y · Cited by 1
Minocycline as an Evidence-Based Adjunct Treatment in Schizophrenia
Kelly, D. L., & Wehring, H. J. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180413-01 · Cited by 1
Neuroinflamation Treatment Options in Resistant Schizophrenia—State of the Art
de Sá, Z. C., Buinho, A., de Oliveira, T. M., Soares, F. R., Rema, J., & Novais, F. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00356-x · Cited by 1
Cytokines and Related Metabolic Markers in Adult Neuropsychiatric Disorders: Possible Roles in Clinical Application
Myint, A.-M., & Schwarz, M. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_10
Investigating neurobiological mechanisms linking depression and inflammation
Hasebe, K. (2017) · Figshare
Gut Microbiota in Brain diseases
Salami, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00040-1
Integrated Metabolomics to Reveal the Impacts of Common Antibiotics based on Drug Resistance Prediction of Gut MicrobiotaPreprint
Gao, P., Huang, M., Ono, N., Kanaya, S., & Altaf-Ul-Amin, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.16.444960
Anti-inflammatory Agents for Patients with Schizophrenia
van Beveren, N. J. M., Çakici, N., & Sommer, I. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-71229-7_22

Authors: Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S.
Affiliations: Razi Hospital (IR)
Roozbeh Hospital (IR)
Kurdistan University of Medical Sciences (IR)
Arak University of Medical Sciences (IR)
Tehran University of Medical Sciences (IR)
Corresponding author: Akhondzadeh, Shahin
ORCID: Farokhnia, Mehdi
Tajdini, Masih
Modabbernia, Amirhossein
Rezaei, Farzin
Salehi, Bahman
Tabrizi, Mina
Akhondzadeh, Shahin
Venue: Psychiatry Research
Publisher: Elsevier BV
Published: 2014-03
Volume: 215
Issue: 3
Pages: 540-546
ISSN: 0165-1781 (ISSN-L)
DOI: 10.1016/j.psychres.2013.12.051
OpenAlex: W2070688969
Cited by: 104
References: 33
Citations by year: 2026: 5 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 11 · 2020: 6 · 2019: 5 · 2018: 16 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 6
FWCI: 10.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Psychiatry Research (publishedVersion)
PubMed (publishedVersion)
Funders: Tehran University of Medical Sciences (11921)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: minocycline, risperidone, schizophrenia, negative symptoms, adjunctive therapy, chronic schizophrenia, PANSS, extrapyramidal symptoms, depression, tolerability, neuroprotection
MeSH terms: Adult, Anti-Bacterial Agents, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Minocycline, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks